

BCIC Sino-US Capital Roadshow

BOSTON CHINESE INVESTMENT CLUB

FRIDAY | CAMBRIDGE, BOSTON
MAY 5, 2 PM | MIT, E51, 70 MEMORIAL DR

波士顿华人投资俱乐部

BOSTON CHINESE INVESTMENT CLUB

BCIC

BOSTON CHINESE
INVESTMENT CLUB



BOSTON CHINESE INVESTMENT CLUB

关于我们 ABOUT US

2010年由波士顿华人金融投资人士发起的平台。协会旨在促进波士顿及其他地区华人金融和投资的交流和讨论，通过组织各种研讨和交流活动，为广大会员提供职业和社交服务，并积极为中国金融业的发展提供人才和建议。协会会员逾2000人，遍布中美各地。

Boston Chinese Investment Club (BCIC) is a non-profit organization founded by TCFA (The Chinese Finance Association) Boston organizers in 2010. It serves as Boston centered platform for exchanging ideas, knowledge, and information in finance and related areas between US and China.

过往活动

Past Events

协会曾成功举办多场活动，嘉宾包括前美国财政部部长Larry Summers，美国证监会前副主席Michael S. Piwowar，及前证监会国际部主任、中投公司副总经理祁斌等，还有中金，中信等及其它投资机构高层。Club held numerous successful events, distinguished guests included: former US Finance Minister Mr. Larry Summers, former U.S. SEC Commissioner Mr. Michael S. Piwowar, former China SEC international department director Dr. Bin Qi, and senior management from CICC, CITIC and other institutions.

日常活动

Ongoing Events

- 每月一次投资相关的主题讲座活动，邀请资深人士分享市场动态及职场经验；
- 定期社交联谊活动如高尔夫大赛、德扑大赛；
- 与 Boston Academy 联合举办的CFA一级培训；
- 定期举行中美资本路演。
- Monthly investment topic information session;
- Regular networking activities such as Golf competition;
- CFA Level I training session with Boston Academy;
- Regular Sino-US capital roadshow.

会员贡献

Member Contribution

协会活跃会员分布于各类著名银行、对冲基金、互助基金、私募和风投等，提供了很好的建立人脉网络的机会。

Active members work in banks, hedge funds, mutual funds, private equity firms and venture capital firms, providing good networking opportunities.



CONTENTS

- Conference agenda
- Biotech teams information
- Quant trading speaker information
- Fintech teams information
- Guests and VIPs
- Sponsors
- Our team

AGENDA

2:00 pm – 5:30 pm Biotech Roadshow

(Investors and Professionals only – venue information will be notified by email to qualified registrants)

8 startup teams, around 20 mins for each team

5:30 pm – 6:15 pm Pizza and Drink

(Hallway in third-floor E51)

6:15 pm – 7:00 pm Quantitative Trading Speaker Session

(E51-345)

Topic: Quant Development and Alpha Decomposition

George Xiang, Professor and PhD adviser at Renmin University of China, Head of Investment at China Post Hongxin Investment, and Head of research at Wuhan Hongyuan Huanqiu

7:00 pm – 9:30 pm Fintech Roadshow

(E51-345)

5 teams in various stage, around 25 mins for each team

BIOTECH



Capten Therapeutics is developing a new class of drugs that will enhance the immunogenicity of cancer cells in a novel way. Our technology uses analogs of the active substance in poison ivy to bond with proteins in cancer cells to produce highly immunogenic hapteneated proteins. We believe that our hapteneated proteins will stimulate an adaptive immune response that will open the door to effective therapeutic options. In particular, we anticipate that our agents will dramatically improve response rates to checkpoint immunotherapies and effect many more cures.

LRRK Therapeutics dedicated to developing novel LRRK2 kinase inhibitor to treat Parkinson disease and neuroinflammation. We had the small molecule US patent licensed from University of Maryland School of Pharmacy, strong academia supports from Prof. Wanli Smith and Prof. Christopher Ross from Johns Hopkins psychiatric department as well as a strong team with industrial experiences. The company is currently working on toxicity study in non-human primate in China as part of the pre-clinical IND package for phase I clinical trial.

We are currently seeking strategic investor to participate in the seed round of \$500k-\$2M.

LRRK
Therapeutics

Gracomics LLC

Gracomic LLC is a Connecticut biotech company with a patent-protected, third generation of biochips technology, after DNA microarray and protein microarray, which belongs to the biochips market of \$17 billion sales. The technology can be used for diagnosis / prognosis of diseases, precision medicine, drug safety and patient stratification in clinical trials.

We have developed the prototype of the product and published its application on the biomarker identification for breast cancer. A protein microarray company wants to license and co-develop the products with us. Another company wants to obtain the exclusive license right of the Gracomics technology.

WntRx Pharmaceuticals Inc.'s early-stage research is focusing on developing novel Wnt pathway inhibitors. Using a variety of innovative methods and cutting-edge technology, our goal is to develop targeted therapeutics to block oncogenic-specific targets in the Wnt pathway. Ultimately, our mission is to alleviate pain and enable a longer, better quality life for patients.



BIOTECH



Neuform Pharmaceuticals Inc, registered in 2014, is a biopharmaceutical company based in Metro Boston area focusing on innovative drug discovery. Our proprietary and patent-protected an adaptive immune response that will open the door to effective therapeutic options. In particular, we anticipate that our agents will dramatically improve response rates to checkpoint immunotherapies and effect many more cures. Drug candidates cover the areas of oncology, neurology, immunology and metabolic disease. Currently the company has more than ten active programs and filed dozens applications to protect the intellectual properties of New Chemical Entities. Among the leading programs, we have achieved substantial progresses and are moving into the stage of conducting necessary studies for IND filing. Our DxH platform continuously generates valuable patents for new programs which aim at improving efficacy and minimizing toxicity. Working with a world-class group of academic investigators, clinical experts, legal advisers and business partners, we dedicate to bringing best-in-class medicines to patients.

ZSFab provides surgeons with patient specific knee surgery packages including 3D printed biocompatible surgical guides and titanium alloyed implants, optimized for shape, and especially the biomechanical properties, with its algorithm. The algorithm takes in the raw CT/MRI data and converts into 3D bone models with the help of surgeons, followed with autonomous modeling of the guides and the biomechanical lattice structures optimization. Proper 3D printers are used to fabricate the guides and implants. The package reduces surgery time, lowers malpractice rate, shortens recovery period, alleviates/ eliminates foreign body sensation and improves satisfaction rate overall. Our team is composed



Cam Med is developing its breakthrough design for a patient-friendly patch pump, the Evopump, which delivers one or multiple injectable medications subcutaneously, more reliably and consistently than self-injections. Invisible under clothing and unobtrusive during sleep and daily activities, the ultra-thin and flexible Evopump overcomes physical and psychological barriers that inhibit the majority of patients from wearing pumps.

BIOTECH

BrainCo Inc. was founded by CEO Bicheng Han in February 2015.

BrainCo was incubated in the Harvard Innovation Lab, BrainCo now has a concrete focus on attention improvement training. With real-time electroencephalography (EEG) analysis and BrainCo's attention training algorithms, users can gradually reach their full potential. In the

Summer of 2016, BrainCo raised \$5.5 million in pre-Series A funding.

In early 2017, BrainCo proudly launched two wearable devices: Focus 1 and Lucy, along with multiple proprietary application systems, at CES

(The International Consumer Electronics Show) in Las Vegas, which was covered extensively by numerous media outlets.

BrainCo started with a handful of distinguished research scientists and engineers who graduated from Harvard/MIT, and now has expanded to 25 full time employees.



BrainCo
your brain controls everything

SPEAKER



George Xiang is a professor and PhD adviser at Renmin University of China. He also is the head of investment at China Post Hongxin Investment and the head of research at Wuhan Hongyuan Huanqiu. In past, George was a senior consultant at CIC, the head of the global fixed income quantitative research at SSgA, a vice president at Loomis Sayles, a quantitative researcher at Conseco Capital Management. George received a PhD in mathematics and MS in computer science from Purdue University. He is CFA and FRM certified and has numerous publications in finance, mathematics, and computer science. He has one patent pending that involves investment technology and products.

FINTECH

Wealthsimple is an investing service that combines user-friendly digital tools and personal financial advice to make investing simple, accessible, affordable and personalized. Founded in 2014, Wealthsimple now serves more than 20,000 clients and was awarded Best Financial Services Website in the World at the 2016 Webbys. We're a values-driven company that believes a passive investment strategy is the best way for our clients to build wealth long-term. We don't pick stocks or "play" the market. We believe in focusing on what you can control: fees, emotions and your own investing habits.



Fund Raising Situations: Total funding of \$45.66M in 3 rounds from 7 investors.

DigitalX is an innovative blockchain development group. DigitalX has leveraged blockchain technology and the distributed ledger system to create AirPocket, a remittance application for secure, low-cost money transfers that integrates blockchain transaction recording, providing

the backbone for a new form of credit verification. The company has also introduced AirID, a patent-pending technology that allows for easy sharing of limited chronological sets of payment records, cryptographically linked on the blockchain. DigitalX was listed on the Australian Securities Exchange (ASX) in June 2014 and is publicly traded as DigitalX Limited (ASX:DCC).

Fund Raising Situations: We are public company in Australia. We are looking to raise funds to market AirPocket and to develop our AirID tech into a suite of B2B products.

Investment Highlights: DigitalX is pivoting after previously being a bitcoin miner, capitalizing on blockchain experience to provide new products and consulting services.



FINTECH



One of the most broken parts of the asset management industry is how investment managers manage currency risk. Each year, thousands of firms are using expensive outsourcing solutions or error-prone Excel spreadsheets to manage \$26T+ in currency exposure, rendering them unprepared for extreme market volatility. Even as lawsuits are being settled for \$BNs against some currency outsourcers, buyside firms continue to utilize these outsourcers, many of which have competing financial interests.

WiseRisk is a subscription-based online currency exposure management platform, which allows managers to manage their currency risk with precision. Our low cost solution automates hedging strategies and includes an advanced compression algorithm that minimizes transaction costs. The WiseRisk platform integrates directly with investment managers' existing investment application network and piggybacks on data already moving around.

Fund Raising Situations: Friends and family investment

Investment Highlights: Products capturing increasing needs; Huge attainable market; Strong team



Cinch is your very own personal CFO. We're creating the world's first comprehensive personal financial manager to optimize your entire financial life. We blend behavioral economics, extensive domain knowledge, advanced algorithm and decision tooling, pricing engines, and a proprietary and complete inventory of all financial products and behaviors to act exclusively in the best interests of the individual. We're launching the "Waze" version of Cinch this year -- giving you hyper-accurate, situationally aware navigation to optimize your financial life and save money. Over time Cinch will offer to act on your behalf -- doing the actual "driving" -- as your always-on, intelligent and loyal personal financial agent.

Cinch is deployed direct-to-consumer, and through aligned third parties such as employers. We eschew all forms of lead generation or embedded financial products to avoid bias and fulfill our fiduciary promise.

Fund Raising Situations: \$8.85 million in 3 rounds

Investment Highlights: Cinch is building the future of autonomous, continuously optimized personal financial

FINTECH

Even-Better is a Quantitative Financial Technology developed by a diverse team of engineers, researchers and financial professionals. It is a web-based platform that transforms historical and real-time data into information package for users to further interact with by researching, exchanging opinions and enhancing the investment decision. At current phase, it provides real-time market investment recommendation based on meta-portfolios to traders and individual investors. It also provides interactive research environment for asset managers and analysts to conveniently use advanced quantitative tools build customized portfolios.



Fund raising situations: 300K in seeding round.

Investment highlights:

1. New way of investment combined both merit of robo-advisory and human trader. Wall street senior asset management practical + phd of data science.
2. Transformed unstructured data to quantity.
3. Interactive platform that everyone can use.

Coalesce.Info is a personalized research application that combines machine learning with human expertise to conduct intelligent searches for business users - dramatically increasing productivity

by filtering and analyzing vast quantities of data faster than humanly possible.



Fund raising situations: In the process of raising a Seed round

Investment highlights:

We filed two patent applications to protect our novel approach for User-Based Machine Learning. Our CEO moderates an AI industry group with almost 2,000 members, providing marketing exposure and recruiting advantage.

VIP

Ordered Alphabetically




Ms Sarah Biller is very active in the FinTech community as an Entrepreneur, Advisor and Investor. She is the co-Founder of the FinTech Sandbox and currently sits on its Board of Directors. Sarah also sits on the Advisory Board of start-ups in solving complex challenges in the robo-advisory, student loans, blockchain and FX trading sectors. She also teaches a graduate level course on the evolution of Financial Technology at Brandeis University.

Sarah was most recently the Head of Innovation Ventures at State Street Bank and its Chief Operating Officer for Innovation. Prior to joining State Street, Sarah was a Principal in the launch of several successful venture-backed start-ups in the FinTech and Life Sciences sectors.

She is the Co-Founder and President of Capital Market Exchange (CMX), a venture-backed predictive analytics platform utilizing investor sentiment to help capital markets professionals anticipate near-term changes in bond and CDS spreads.

Sarah has also held roles at Fidelity Investments; worked on MCI's corporate venture team; and launched and led research divisions for Fortune 500 CFO's and treasurers at the Corporate Executive Board. She studied Finance at West Virginia University and George Washington University.

Mr. Wenbo Du is the founder and CEO of Long Pharmaceuticals. He was the former Genzyme Global Drug Safety Officer, Senior Director of AMAG, Associate Director of KV Pharmaceutical, and Medical Director of Valeant, etc. He holds a PhD from National University of Singapore, a Bachelor of Medicine from Beijing Medical University, and an MBA from USC.



Mr. José Estabil brings 20+ years of experience in translating technology into high growth businesses with cumulative \$1B market impact. He is currently developing a network of entrepreneurial ecosystem hubs -InTeaHub- in the US and European technology centers on behalf of ITH, an early stage venture fund. He held leadership roles at IBM, KLA-Tencor, Schlumberger YES, and ArcticSand. His portfolio of international entrepreneurial activities includes projects in Mexico (IADB), Cuba (Miami Dade College), Portugal (MIT), Italy (TT Ventures), and Japan (Schlumberger YES: Acq. AMAT). José was part of the MIT team that established the Skolkovo Institute of Science and Technology in Moscow, Russia, where he became Dean of International Research.

VIP

Ordered Alphabetically



Mr. Yudong Hou is the Co-founder and Managing Director of Eastern Link Capital. Mr. HOU previously served as an Executive Vice President for investment banking, investment management and a brokerage division of Guang Fa Securities. He also served as a Board of Director and Executive Vice President for Guang Fa Northern Securities. Previously, Mr. Hou worked at IDG Technology Venture Investment (now known as IDG Capital) for five years as Analyst and was promoted to CFO. He has been one of the key managers for IDGVC's early investments and expansion in China.

Mr. Hou holds an MBA from Columbia University, a Master degree in Finance from Suffolk University and a BS in Accounting from North China University of Technology.

Dr. Shidong Jia (Founder & CEO): Former Scientist at Genentech and Lab Head at Novartis Institutes for BioMedical Research (NIBR). 21 years of experience in cancer research, identified p110 β as novel drug target for PTEN-deficient tumors, a finding that laid the foundation for clinical development of p110 β inhibitors in cancer; 1st authorship publication in Nature. 5 years of industry experience spearheading the biomarker strategy and drug & diagnostics codevelopment efforts in support of oncology pipeline at various stages culminated by the Lifecycle Investment Point (LIP) achievement of driving Phase II into Phase III pivotal clinical trials. Member of the National Cancer Institute Special Emphasis Panel Review Committee.

Editor-in-Chief of "Journal of Circulating Biomarkers", Springer book "Extracellular Vesicles: Methods and Protocols". Recipient of the "Young Investigator" award at the Fourth Asian Congress for Microcirculation and the "P.A.R.T. Investigatorship Award" at Dana-Farber Cancer Institute, Harvard Medical School. MD, PhD and postdoc from Harbin Medical University, Peking Union Medical College and Harvard University, respectively.



Mr. Yin Jie is an executive officer of Kaitai capital and Kaitai Chuangfu Fund. He oversees the investment in healthcare sector. He led and participated several deals including YULONG Biomedical Group (clinical test laboratory), Yun Pacs (platform of medical imaging), QY NODE (cloud-based genomic data management and bioinformatics platform), Purmed (healthcare service provider), icareTek (Intelligent monitoring device), Yunyin Medicine (cancer liquid biopsy), Carsgen (immuno-oncology) and so on. Mr. Yin obtained his master degree of economics from Zhejiang University.

VIP

Ordered Alphabetically

Ms Xin Liu is the founder of InTeahouse Inc. She founded InTeahouse in 2014 with a mission of bridging local innovators and international investors. Prior to that, Xin served as the CEO of HiPower Energy Group. During the same time, she co-founded KingL and Capital.



Dr. Shi-Jiang (John) Lu is the President and CEO of VcanBio CTB. He is also the President and CEO of HebeCell Corporation. Before joining VcanBio Center for Translational Biotechnology and HebeCell, John was the Senior Director of Research at Ocata Therapeutics, which was recently acquired by Astellas, the 2nd largest pharmaceutical company of Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. John has been conducting translational researches and novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. The goal of his research is to generate hESC/iPSC-derived products for the treatment of human diseases. He has extensive experience in process development and large-scale production of human pluripotent stem cell derivatives for clinical applications.

Dr. Shen Luan is Director of Regulated Products and Interim Director of BRIMS Center at Thermo Fisher Scientific. He develops and drives the global market entry strategy for regulated products. As Interim Director of BRIMS Center, Shen Luan leads efforts to develop MS-based workflows for biomarker discovery and validation. Prior to Thermo Fisher Scientific, Shen co-founded Berg Diagnostics (now part of Berg Health) in 2010 and served as the founding President and CTO. He was named as COO in 2011. Shen started his career with Thermo Fisher Scientific holding various positions including Engineering Manager, Research Manager, and Product Manager.

Shen received a Ph.D. in Analytical Chemistry from Iowa State University and a B.S. in Chemistry from Peking University. He is a member of BayHelix, an invitation-only organization of leaders of Chinese heritage in the global life sciences and healthcare community.



VIP

Ordered Alphabetically



Mr. Albert Ma is the Chief Innovation Officer of Insigma Hengtian Software, Ltd. He has over 30 years of IT management and software development experience. Before joining Hengtian, Mr. Ma was the Chief Information Officer of the State Street Technology Center for several years in Hangzhou, China. He was the core team member in setting up the IT operation locally and migration of strategic applications to the Hangzhou office.

As the company's Chief Innovation Officer, Mr. Ma manages the R&D and innovation activities of the company. He makes leading research efforts in technical solutions in Big Data Analytics, Cloud Computing, Mobile, Machine Learning and Software Engineering Automation.

Mr. Ma graduated from the University of Queensland with a Master's Degree in Technology Management and an MBA from the University of Hull. He is a certified Project Management Professional and Certified IT Professional.



Mr. Tony Tian is the Managing Partner at Kendall Venture (a.k.a. CUBIC Venture Fund) and the President at NECINA. Tony Tian is an enterprise business veteran and early-stage investor. His investment areas include Intelligent devices, Enterprise hardware/software and Healthcare. Tony is passionate about delivering values and building successful enterprises. Tony has helped various start-ups to transit from early stage to middle stage. His involvements include Logic Ink, Project Joy, TVision Insights, Soteria Networks, EnGauge, Vibronix etc.

Prior to Kendall Venture Tony was a seasoned Enterprise product veteran.

Mr. Zhongwei Wu (Wade) is the Co-Founder of Mass Ave Capital. Zhongwei has fifteen years investing experience in China. He is one of the founders of Oriental Fortune Capital, the top twenty Chinese venture capital company in the past decade. He has invested in over ten successful projects in China including SLTX (002446), JXHW (300095), CHJH (002256) and has continued to be a shareholder of two early stage companies in China, Qianmai Medical Lab and Seadragon Education. In 2016, he set up Mass Ave Capital in Boston with his partners to continue his venture capital in the U.S.. Mass Ave Capital has invested three portfolios in one year, including Gigavation (Cyber security), Meta (AR), and Oculii (4D sensor).



VIP

Ordered Alphabetically



Ms Kate Xiong is the Founder of First Rice Capital (FRC). FRC is an angel investment fund focused on deep tech start-ups in Cambridge MA. Through our contacts and various resources in China/India, we seek to help these deep tech companies to grow and expand into China/India earlier and faster. Prior to that, Kate was the Senior Director of International Wealth Management Division at Ant Financial Group. Prior to Ant Financial Group, Kate was a Fund Manager at Libra Capital, an Alibaba affiliate. Previously she held various fund management roles at Highbridge Capital and Goldman Sachs Asset Management.

Kate received her MBA from Carnegie Mellon and her MS in Industrial Management Engineering from Huazhong University of Science and Technology.



Mr. Chong Xu focuses primarily on bio-pharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company's Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore. Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang

Jiayi (Charley) Xu, Venture Partner. He has a B.S of Applied Chemistry from Peking University and a Ph.D of Chemistry from Stanford University. Prior to joining Frees VC, Jiayi had over ten years of experience in new drug discovery working in pharmaceutical companies, Johnson and Johnson and Merck. He was involved in a variety of research projects in the therapeutic areas of diabetes, HIV, cancer and cardiovascular diseases. He is the co-author of over 30 publications and co-inventor of a dozen patent applications. Jiayi is interested in investments of biotechnology, medical devices and pharmaceutical industry.



VIP

Ordered Alphabetically

Dr. Qin Yan is Associate Professor and Director of Epigenetics Program in the Department of Pathology at Yale Medical Schools. He is also a member of Yale Cancer Center and Yale Stem Cell Center. He received his B.S. degree from the University of Science and Technology of China, and his Ph.D. training with Drs. Joan and Ronald Conaway at the University of Oklahoma and Stowers Institute for Medical Research. He completed his postdoctoral training with Dr. William Kaelin at the Dana-Farber Cancer Institute and Harvard Medical School. He has received numerous awards, including Era of Hope Scholar Award from DoD Breast Cancer Research Program, V Scholar Award, and Stewart Scholar Award.



The focus of his laboratory is to elucidate the roles of epigenetic aberrations that drive tumor initiation and progression and to translate the findings to the clinic. He co-discovered epigenetic enzyme KDM5A, demonstrated oncogenic roles of KDM5 enzymes in various cancers, and identified the “first-in-class” KDM5 inhibitors. He leads the KDM5 inhibitor projects for both National Cancer Institute Experimental Therapeutics (NExT) program and Program in Innovative Therapeutics for Connecticut’s Health (PITCH). The goals of these projects are to develop novel potent KDM5 inhibitors for cancer treatment.



Ms Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May, 2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Ms Cynthia Zhang Qian is the Managing Director and Head of Private Equity at ChinaAMC Capital. Cynthia is the founder of the private equity business of China Asset Management. She has more than ten years of experience in middle and late stage PE investment and secondary market investment, with a focus on TMT, consumer discretionary, consumer staples, healthcare and FI sectors.

In the seven years at China Asset Management, Cynthia has accumulated valuable resources and developed in-depth experience in investing in both China and global markets. The major PE investments that Cynthia has led includes DianPing.com (now Internet Plus Holdings), Didi, Meitu.com, Kingsoft Cloud, Sinopec Marketing, Man Wah (1999.HK), Alibaba(BABA.US) and CGN(1816.HK), etc.

Before joining China Asset Management, Cynthia worked at Merrill Lynch, UBS and Delta Partners.



VIP

Ordered Alphabetically



Mr. Peter Zhu, Partner of Boston Angels Club, is a big data expert and a seasoned entrepreneur. He founded Fortelligent in 2000, which was acquired by WPP in 2004, established FocusKPI in 2009, which has an annual 25% increase in profits, and founded Brilliant in 2015 which is currently evaluated at \$25 million with M&A offerings.

SPONSOR

BCIC Sponsor

Eastern Link Capital (ELC) is a China focused private equity fund registered with Asset Management Association of China(AMAC). EL Capital manages four Renminbi funds, all of which either anchored by the prestige joint venture fund of funds of China Development Bank and Suzhou Industrial Park or the Beijing Municipal Government owned fund of funds. ELC's founding partners worked for IDG Capital and Guang Fa Securities, one of the largest investment banks in China. Capital invests in late stage companies and middle market buyout in consumer, healthcare service & medical devices and technology. EL Capital has been



Hengtian is an innovative company geared to providing advanced technology solutions which enable businesses to accelerate their new product development. Hengtian was created in 2004 as an alliance among Zhejiang University (A Top Three University in China), State Street Corporation (A Major U.S. Financial Institution),

and Insigma Technology (a Global Outsourcing 100 Company)). Hengtian provides advanced technology research and development, global sourcing solutions and

SPONSOR

Event Sponsor

InTeahouse, a global network of innovators, entrepreneurs, and investors, launched its InSeven Investment Program on April 3, 2017. This program helps startups grow faster through an investment of \$70, 000; a year of collaborative work space; access to an international network of advisors, mentors, investors, and customers; and follow-on capital options. InSeven launches with a pitch competition on May 13, 2017.

Startups interested in participating may view additional information and apply by April 30 11:59pm at:

<http://inteahouse.com/inseven/>.



InSeven Investment Program Pitch Competition

May 13, 2017

Registration Deadline April 30
inteahouse.com/inseven/

The InSeven Investment Program by InTeahouse helps startups accelerate growth through an investment of \$70,000, a year of collaborative workspace, access to an international network of advisors, mentors, investors, and customers, and follow-on capital options.



InTeahouse

www.inteahouse.com

To apply and learn more, please visit [Inteahouse.com/inseven/](http://inteahouse.com/inseven/)

OUR TEAM

BCIC

Co-Chair	Kun Yang	Ph.D, CFA, Director of Panagora Asset Management
Co-Chair	Min Yi	CFA, Senior Analyst of Fed Home Loan Bank

Biotech Team

Director	Yuchao Li	MBA of Boston College
Director	Qingwei Sun	Analyst of Lumleian
Director	Suxiang Peng	Co-founder & Managing Director of Spartacus Capital BVI

QuantTrading Team

Director	James Wang	Ph.D, Fixed Income Analyst of Putnam Investment
Director	Yuan Yuan	Research Associate of Arrowstreet Capital

Fintech Team

Director	Ying Guo	Quantitative Predictive Modeler of Sun Life Financial
Director	Sherry Huang	Data Scientist of Altisource
Director	Elise Zhang	Quantitative Analyst of State Street

Director of Marketing/Communication/PR Wenyu Xiong Investment Analyst of Choate Investment Advisors

BCIC Vice Chair, Social Platform Admin	Xiaoping Zhou	Ph.D, Quantitative Analyst of Citizens Bank
Website	Apollo Chow	Systems Analyst of Wellington Management
Brand Image Designer	Yichen Zhu	Ph.D Candidate of Tongji University
Treasurer	Zaoping Li	Ph.D, Treasury Analyst of Citizens Financial Group
China Regional Director	Stanley Shi	Assistant Director of Guotal JunAn Securities

Volunteers Wanting Qian, Chuanchuan Zhang, Vito Xiaohui Qin, Yujing Li, Xi Zhao, Yitong Huang, Joan Cao, Yuan.Y. Wang, Han Wang, Yang Yang

Thank you for all the volunteer's help in the process!